Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SANA
DateTimeSourceHeadlineSymbolCompany
01/08/20254:05PMGlobeNewswire Inc.Sana Biotechnology to Present at theĀ 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SANASana Biotechnology Inc
01/07/20254:05PMGlobeNewswire Inc.Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without ImmunosuppressionNASDAQ:SANASana Biotechnology Inc
12/16/20244:33PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
12/02/20249:00AMGlobeNewswire Inc.Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus ErythematosusNASDAQ:SANASana Biotechnology Inc
11/26/20246:20PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
11/25/20245:40PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
11/25/20244:05PMGlobeNewswire Inc.Sana Biotechnology to Present at December 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
11/08/20249:14AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
11/08/20249:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
11/08/20249:00AMGlobeNewswire Inc.Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
11/04/20244:30PMGlobeNewswire Inc.Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025NASDAQ:SANASana Biotechnology Inc
10/23/20248:00AMPR Newswire (US)Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering IntelligenceNASDAQ:SANASana Biotechnology Inc
10/21/20245:19PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
10/08/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
10/03/20248:00AMPR Newswire (US)Invaio Sciences Appoints AndrƩ Andonian as Chairman of the Board of DirectorsNASDAQ:SANASana Biotechnology Inc
09/30/20244:05PMGlobeNewswire Inc.Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day ConferenceNASDAQ:SANASana Biotechnology Inc
09/12/20244:36PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
08/29/20244:05PMGlobeNewswire Inc.Sana Biotechnology to Present at September 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
08/26/20244:05PMGlobeNewswire Inc.Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:SANASana Biotechnology Inc
08/08/20244:21PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
08/08/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
08/08/20244:05PMGlobeNewswire Inc.Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
08/06/20246:30AMPR Newswire (US)Flagship Pioneering Announces Appointment of Raj Panjabi as Senior PartnerNASDAQ:SANASana Biotechnology Inc
07/15/20244:12PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:SANASana Biotechnology Inc
06/07/20244:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
06/07/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
05/21/20249:00AMGlobeNewswire Inc.Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntingtonā€™s Disease and Other GliaNASDAQ:SANASana Biotechnology Inc
05/08/20244:49PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SANASana Biotechnology Inc
05/08/20244:21PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
05/08/20244:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA